Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
Saved in:
| Title: | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. |
|---|---|
| Authors: | Files DC; Department of Internal Medicine, Pulmonary, Critical Care, Allergy and Immunology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America., Tacke F; Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany., O'Sullivan A; AbbVie Inc., North Chicago, Illinois, United States of America., Dorr P; AbbVie Inc., North Chicago, Illinois, United States of America., Ferguson WG; AbbVie Inc., North Chicago, Illinois, United States of America., Powderly WG; John T. Milliken Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine in St Louis, St Louis, Missouri, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2022 Jun 24; Vol. 18 (6), pp. e1010547. Date of Electronic Publication: 2022 Jun 24 (Print Publication: 2022). |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1553-7374 |
|---|---|
| DOI: | 10.1371/journal.ppat.1010547 |
